Reports Q3 revenue $1.007B, consensus $1.36B. “We continue to grow revenue at or above market thanks to the strength of established and emerging brands that cover the entire spectrum of eye health,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our multi-year effort to rewire the company is gaining traction as we methodically review and improve areas critical to our success, with a focus on sales and supply chain.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLCO:
- Bausch + Lomb price target lowered to $20 from $23 at BofA
- Bausch + Lomb price target lowered to $20 from $21 at RBC Capital
- Bausch + Lomb price target lowered to $18.50 from $20 at Morgan Stanley
- Bausch + Lomb price target lowered to $21 from $22 at H.C. Wainwright
- Eli Lilly deal for Point puts radiopharma names in spotlight
